

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 018623-014100US

Assistant Commissioner for Patents
Washington, D.C. 20231

On 27 April 2001

TOWNSEND and TOWNSEND and CREW LLP

By Halinder Chaght

RECEIVED

MAY 02 2001

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SETTE *et al.*

Application No.: 09/412,863

Filed: October 5, 1999

For: INDUCING CELLULAR IMMUNE
RESPONSES TO HUMAN
IMMUNODEFICIENCY VIRUS-1
USING PEPTIDE AND NUCLEIC ACID
COMPOSITIONS

Examiner: Schwadron, Ronald B.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Examiner's Communication mailed March 27, 2001, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

In the Specification:

Please replace the paragraph that was inserted at page 1, line 35, following the Statement Regarding Federally Sponsored Research or Development in the amendment submitted November 21, 2000 with the following paragraph in accordance with § 1.52(e)(5):